207 related articles for article (PubMed ID: 27430122)
1. Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: Should we get to the PK/PD root of the paradox?
Del Bono V; Giacobbe DR; Marchese A; Parisini A; Fucile C; Coppo E; Marini V; Arena A; Molin A; Martelli A; Gratarola A; Viscoli C; Pelosi P; Mattioli F
Virulence; 2017 Jan; 8(1):66-73. PubMed ID: 27430122
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing Klebsiella pneumoniae.
Cojutti P; Sartor A; Righi E; Scarparo C; Bassetti M; Pea F
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28760900
[TBL] [Abstract][Full Text] [Related]
3. Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae?
Pea F; Della Siega P; Cojutti P; Sartor A; Crapis M; Scarparo C; Bassetti M
Int J Antimicrob Agents; 2017 Feb; 49(2):255-258. PubMed ID: 28012683
[TBL] [Abstract][Full Text] [Related]
4. Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems.
Machuca I; Gutiérrez-Gutiérrez B; Gracia-Ahufinger I; Rivera Espinar F; Cano Á; Guzmán-Puche J; Pérez-Nadales E; Natera C; Rodríguez M; León R; Castón JJ; Rodríguez-López F; Rodríguez-Baño J; Torre-Cisneros J
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559247
[TBL] [Abstract][Full Text] [Related]
5. In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase.
Wiskirchen DE; Koomanachai P; Nicasio AM; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2011 Apr; 55(4):1420-7. PubMed ID: 21282442
[TBL] [Abstract][Full Text] [Related]
6. Comparative serum bactericidal activity of meropenem-based combination regimens against extended-spectrum beta-lactamase and KPC-producing Klebsiella pneumoniae.
Gaibani P; Lombardo D; Bartoletti M; Ambretti S; Campoli C; Giannella M; Tedeschi S; Conti M; Mancini R; Landini MP; Re MC; Viale P; Lewis RE
Eur J Clin Microbiol Infect Dis; 2019 Oct; 38(10):1925-1931. PubMed ID: 31278562
[TBL] [Abstract][Full Text] [Related]
7. Use of Monte Carlo simulation to evaluate the efficacy of tigecycline and minocycline for the treatment of pneumonia due to carbapenemase-producing Klebsiella pneumoniae.
Ni W; Li G; Zhao J; Cui J; Wang R; Gao Z; Liu Y
Infect Dis (Lond); 2018 Jul; 50(7):507-513. PubMed ID: 29316830
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of tigecycline, polymyxin, gentamicin, meropenem and associations in experimental Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae non-lethal sepsis.
Toledo PV; Tuon FF; Arend L; Aranha Junior AA
Braz J Infect Dis; 2014; 18(5):574-5. PubMed ID: 24907469
[No Abstract] [Full Text] [Related]
9. Activity of Tigecycline in combination with Colistin, Meropenem, Rifampin, or Gentamicin against KPC-producing Enterobacteriaceae in a murine thigh infection model.
Michail G; Labrou M; Pitiriga V; Manousaka S; Sakellaridis N; Tsakris A; Pournaras S
Antimicrob Agents Chemother; 2013 Dec; 57(12):6028-33. PubMed ID: 24060874
[TBL] [Abstract][Full Text] [Related]
10. In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: the activity of the double-carbapenem regimen is related to meropenem MIC value.
Oliva A; Scorzolini L; Cipolla A; Mascellino MT; Cancelli F; Castaldi D; D'Abramo A; D'Agostino C; Russo G; Ciardi MR; Mastroianni CM; Vullo V
J Antimicrob Chemother; 2017 Jul; 72(7):1981-1984. PubMed ID: 28369424
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
Bulik CC; Christensen H; Li P; Sutherland CA; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2010 Feb; 54(2):804-10. PubMed ID: 19995927
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of tigecycline alone or in combination for experimental infections by KPC carbapenemase-producing Klebsiella pneumoniae.
Fergadaki S; Renieris G; Machairas N; Sabracos L; Droggiti DI; Misiakos E; Giamarellos-Bourboulis EJ
Int J Antimicrob Agents; 2021 Sep; 58(3):106384. PubMed ID: 34161789
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates.
Gaibani P; Lombardo D; Lewis RE; Mercuri M; Bonora S; Landini MP; Ambretti S
J Antimicrob Chemother; 2014 Jul; 69(7):1856-65. PubMed ID: 24648503
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of ceftazidime-avibactam in various combinations for the treatment of experimental osteomyelitis due to Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae.
Davido B; Crémieux AC; Vaugier I; Gatin L; Noussair L; Massias L; Laurent F; Saleh-Mghir A
Int J Antimicrob Agents; 2023 Jan; 61(1):106702. PubMed ID: 36476965
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic-pharmacodynamic modelling of meropenem against VIM-producing Klebsiella pneumoniae isolates: clinical implications.
Tsala M; Vourli S; Kotsakis S; Daikos GL; Tzouvelekis L; Zerva L; Miriagou V; Meletiadis J
J Med Microbiol; 2016 Mar; 65(3):211-218. PubMed ID: 26697851
[TBL] [Abstract][Full Text] [Related]
16. KPC-producing Klebsiella pneumoniae bloodstream isolates from Brazilian hospitals: What (still) remains active?
Antochevis LC; Magagnin CM; Nunes AG; Goulart TM; Martins AS; Cayô R; Gales AC; Barth AL; Zavascki AP
J Glob Antimicrob Resist; 2018 Dec; 15():173-177. PubMed ID: 30071353
[TBL] [Abstract][Full Text] [Related]
17. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.
Pournaras S; Vrioni G; Neou E; Dendrinos J; Dimitroulia E; Poulou A; Tsakris A
Int J Antimicrob Agents; 2011 Mar; 37(3):244-7. PubMed ID: 21236643
[TBL] [Abstract][Full Text] [Related]
18. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study.
Tumbarello M; Trecarichi EM; De Rosa FG; Giannella M; Giacobbe DR; Bassetti M; Losito AR; Bartoletti M; Del Bono V; Corcione S; Maiuro G; Tedeschi S; Celani L; Cardellino CS; Spanu T; Marchese A; Ambretti S; Cauda R; Viscoli C; Viale P;
J Antimicrob Chemother; 2015 Jul; 70(7):2133-43. PubMed ID: 25900159
[TBL] [Abstract][Full Text] [Related]
19. Long-term, low-dose tigecycline to treat relapsing bloodstream infection due to KPC-producing Klebsiella pneumoniae after major hepatic surgery.
Morelli L; Tartaglia D; Furbetta N; Palmeri M; Ferranti S; Tagliaferri E; Di Candio G; Mosca F
Int J Infect Dis; 2015 Jul; 36():4-5. PubMed ID: 25975648
[TBL] [Abstract][Full Text] [Related]
20. Relationship between adverse drug reactions to antibacterial agents and the Klebsiella pneumoniae carbapenemase-producing (KPC) Klebsiella pneumoniae outbreak: insight from a pharmacovigilance study.
Gatti M; Raschi E; De Ponti F
BMC Pharmacol Toxicol; 2019 Nov; 20(1):65. PubMed ID: 31718688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
